Skip to main content

Drug Interactions between cobicistat and estradiol / norethindrone / relugolix

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

norethindrone cobicistat

Applies to: estradiol / norethindrone / relugolix and cobicistat

Consumer information for this interaction is not currently available.

ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration of ritonavir or cobicistat alone or in combination with other antiretroviral agents may increase or decrease the plasma concentrations of hormonal contraceptives. Increases in estrogens and decreases in progestins are the predominant effect seen when used in combination with ritonavir or cobicistat. However, ritonavir or cobicistat formulations have also been associated with increased plasma concentrations of some transdermal formulations of ethinyl estradiol and reduced plasma concentrations of norethindrone. In a pharmacokinetic study, 22 of 23 healthy women who received single doses of an oral contraceptive containing ethinyl estradiol 50 mcg and ethynodiol 1 mg had reduced serum levels of ethinyl estradiol following the addition of ritonavir (500 mg twice a day) for 2 weeks. Specifically, the systemic exposure (AUC) decreased by 41%. In additional pharmacokinetic studies, the AUC of ethinyl estradiol decreased by 30% and 25% when used in combination with darunavir-cobicistat and elvitegravir-cobicistat, respectively. Furthermore, the AUC of drospirenone increased 2.3-fold following coadministration with atazanavir-cobicistat. The exact mechanism of this interaction is unknown but decreases in plasma concentrations of hormonal contraceptives may involve ritonavir- and cobicistat-mediated induction of glucuronosyltransferase or CYP450 1A2 or 2C9 and increases in plasma concentrations of hormonal contraceptives may involve ritonavir- and cobicistat-mediated inhibition of CYP450 3A4.

MANAGEMENT: Women using hormonal contraceptives should be advised of the risk of breakthrough bleeding and unintended pregnancy during concomitant therapy with formulations containing ritonavir or cobicistat. Patients should also be monitored for signs of estrogen or progestin toxicity including ALT elevations, insulin resistance, dyslipidemia, acne, and venous thrombosis. Alternative or additional methods of contraception should be used during and for at least 4 weeks after treatment with formulations containing ritonavir or cobicistat. If a combination oral contraceptive pill is used, a regimen containing at least 35 mcg of ethinyl estradiol per day or equivalent should be selected for most ritonavir-containing regimens and at least 30 mcg of ethinyl estradiol per day or equivalent are recommended by some authorities for most cobicistat-containing regimens. Product labeling for the antiretroviral therapy and/or the hormonal contraceptive should be consulted for specific dosing recommendations related to hormonal contraception. For emergency contraception, a non-hormonal emergency contraceptive (e.g., copper intrauterine device) is considered preferable. No precautions or recommendations are available for women using hormone-releasing intrauterine systems, but a significant interaction with these systems is thought to be unlikely due to their local action.

Major

cobicistat relugolix

Applies to: cobicistat and estradiol / norethindrone / relugolix

Cobicistat may significantly increase the blood levels of relugolix. This may increase the risk and/or severity of side effects such as hot flushes; weight gain; decreased sex drive; erectile function difficulties; muscle and joint pain; constipation; diarrhea; increases in glucose, triglyceride (fat), and liver enzyme levels; and decreased hemoglobin levels. It may also increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. If you do have to take both medications, you should take relugolix first, then take cobicistat after at least 6 hours to minimize the effects of the interaction. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Drug and food interactions

Moderate

norethindrone food

Applies to: estradiol / norethindrone / relugolix

Grapefruit juice may increase the blood levels of certain medications such as norethindrone. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with norethindrone. However, if you have been regularly consuming grapefruit or grapefruit juice with the medication, then it is advisable for you to talk with your doctor before changing the amounts of these products in your diet, as this may alter the effects of your medication. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.

Minor

estradiol food

Applies to: estradiol / norethindrone / relugolix

Information for this minor interaction is available on the professional version.

Minor

norethindrone food

Applies to: estradiol / norethindrone / relugolix

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.